LDL-C lowering in patients treated with bempedoic acid in a real-world cohort
Patients initiating BA and BA + EZE experienced early and sustained LDL-C improvements. The greatest reductions were in patients with continuous use and patients with no evidence of prior statin use, underscoring the importance of long-term adherence and treating patients not on statin therapy.
Authors
- Evelyn Sarnes
- Dave Lewandowski
- Muthiah Vaduganathan (ORCID: https://orcid.org/0000-0003-0885-1953)
- Maryam Ajose
- Mac Bonafede
- James O. Nelson
- LeAnne Bloedon
Institutions
- Brigham and Women's Hospital (US)
- Esperion Therapeutics (United States) (US)
Publication Details
- Journal
- Atherosclerosis Plus
- Published
- 2026-02-04
- DOI
- https://doi.org/10.1016/j.athplu.2026.01.007
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00